The global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market is estimated to have reached $13.40bn in 2018 and is expected to grow at a CAGR of 4.43% in the first half of the forecast period. The stimulants submarket held 75% of the global Attention Deficit Hyperactivity Disorder (ADHD) Market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 151-page report you will receive 124 charts– all unavailable elsewhere.
The 151-page report provides clear detailed insight into the ADHD market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by leading drugs: • Amphetamine • Methylphenidate • Lisdexamfetamine • Dexmethylphenidate • Atomoxetine • Guanfacine • Clonidine • Other Drugs
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by drug type: • Stimulants • Non-stimulants
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by patient type: • Adult • Children
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 national market: • The U.S. • Germany • France • The U.K. • Italy • Spain • China • Japan • India • Brazil • Russia
• This report discusses the selected leading companies: • Eli Lilly • Johnson and Johnson • Lupin Limited • Mallinckrodt & Co. • Neos Therapeutics • Pfizer Inc. • Purdue Pharma L.P. • Takeda Pharmaceuticals
• This report provides a SWOT Analysis and Porter’s Five Forces Analysis of the Attention Deficit Hyperactivity Disorder Drugs market.
• Key questions answered by this report: • How is the ADHD market evolving? • What is driving and restraining the ADHD market? • What are the market shares of each segment of the overall ADHD market in 2018? • How will each ADHD submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029? • How will the market shares for each ADHD’s submarket develop from 2018 to 2029? • Which individual products will prevail and how will these shifts be responded to? • What will be the main driver for the overall market from 2018 to 2029? • How will political and regulatory factors influence the regional markets and submarkets? • Will leading national vaccine markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? • How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what are their prospects over the forecast period? • How will the industry evolve during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Overview
1.2 Global ADHD Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Attention Deficit Hyperactivity Disorder
2.1 History of ADHD
2.1.1 ADHD Medication Timeline
2.2 Signs and Symptoms
2.2.1 Inattention
2.2.2 Hyperactivity-Impulsivity
2.2.3 Impulsiveness
2.3 When can ADHD be diagnosed?
2.4 Side Effects & Risk Factors
2.5 Treatment and Therapies
2.5.1 Medication
2.5.2 Stimulants
2.5.3 Non-stimulants
2.5.4 Psychotherapy
2.5.5 Social Skills Training
2.6 Most Common Disorders That Can Accompany ADHD?
2.7 Blockbuster ADHD Drugs in 2018 - Leading Brands
3. ADHD: World Market Forecast 2019-2029
3.1 ADHD Market Overview, 2018
3.2 The World Attention Deficit Hyperactivity Disorder Market
3.3 World Attention Deficit Hyperactivity Disorder Market: Sales Forecast 2019-2029
3.4 Changing Market Shares by Region 2018-2029
3.5 ADHD Market: Drivers and Restraints 2019-2029
3.5.1 ADHD Market: Drivers 2019-2029
3.5.2 Increase in Prevalence of the ADHD
3.5.3 Rising Government Support
3.5.4 Growing Number of Regulatory Approvals for Drugs
3.5.5 Escalating of Mental Healthcare Awareness
3.5.6 ADHD Market Restraints: 2019-2029
3.5.7 Drug Abuse is a major factor that limits market growth
3.5.8 Stringent Government Regulations
3.5.9 Lack of ideal treatment for ADHD
3.5.10 The social stigma of ADHD and other mental illness
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
